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SUMMARY
Our clinical and experimental experience with chemo-
therapy of bladder tumours is reviewed. The routes of
drug administrations, drug dosages and combinations,
are presented. Adjuvant radiotherapy and chemoprophy-
laxis of certain tumours are discussed.
S. Air. Med. J., 48, 631 (1974).
In spite of the fact that chemotherapy of bladder tumours
was attempted at the beginning of this century in the
form of topical treatment with phenol and podophyllin,
it can be said that modern chemotherapy started only
after the discovery that nitrogen mustard was effective in
the treatment of some human tumours.
Anticancer chemotherapy became of significant value
only during the past 20 years, following the preliminary
screening of a large number of drugs, many of which
are presently in clinical use.
The agents commonly employed can be divided into
4 main groups: alkylating agents, antimetabolites, mitosis-
blocking agents and antibiotics, apart from hormones and
some other drugs that cannot be included in these groups.
A more logical classification would be one that takes
into account the time at which the various drugs act
along the course of the reproductive cycle of the cell,
namely at the S phase, during which DNA synthesis takes
place; at the G I and G2 phases, which respectively precede
and follow the S phase, or in the mitotic phase. Further-
more, cycle-non-specific drugs are those that are able to
act apart from the reproductive cycle, namely during the
GO or interkinetic phase, at least if administered in high
doses.
Chemotherapeutic agents have greatly improved the
prognosis of leukaemia and malignant lymphoma, but
even some solid tumours can undergo partial or total
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regression. Such remissions are often long-lasting and
sometimes apparently permanent and definitive. However,
this applies only to some tumours, such as nephroblastoma
or metastatic testicular neoplasia, which display a high
reproductive activity and can therefore be easily affected
by drugs acting on proliferating cells.
Slowly-growing tumours such as renal, vesical and
prostatic carcinomas are, however, not very sensitive to
chemotherapy, especially if their reproduction rate is
lower than that of normal tissues with high proliferating
activity, such as the bone marrow or the intestinal
crypts. The causes of the low therapeutic index, as well as
the limited usefulness of chemotherapy in these tumours,
are clearly understandable.
Such tumours can be affected only by using high
doses for prolonged periods of time, at the risk of
severe toxicity and even lethal side-effects. Medullary
aplasia, stomatitis and digestive symptoms are the .most
frequent manifestat;ons of drug toxicity. Many anticancer
drugs have immunodepressive effects also, and may there-
fore give rise to a further weakening of the host defences
against infection and the tumour itself.
If lack of selectivity of anticancer drugs were absolute,
useful chemotherapy of slowly-growing tumours such
as renal, vesical and prostatic carcinomas would be
virtually impossible. There is, nevertheless, some degree
of selectivity, as shown by the fact that various drugs can
produce different side-effects and display a particular
spectrum of activity. Selectivity may be dependent upon
differences in penetration of drugs through the cell mem-
branes, on various modalities of fixation in nuclei of
different tissues, or even on different patterns of transport,
activation or breakdown in various healthy and neoplasti.::
tissues.
Particular advantages can be obtained by local or
regional techniques of administration that give rise to
high drug concentrations in the affected tissues. along
with reduced general toxicity. Despite these methods,
which cannot always be applied, chemotherapy of car-
cinomas still remains almost devoid of consistent efficacy.
Prostatic and vesical carcinomas are scarcely suitable
for intra-arterial treatment, which usually involves the
need for surgical cannulation of afferent vessels, with-
out any possibility of limiting the escape of the drug into
the systemic venous circulation. The effect of such an
escape can be prevented by simultaneous haemodialysis
or forced diuresis. We have shown in the dog that toxic
or even lethal doses of alkylating agents (Trenimon), or
antimetabolites (5-f1uoro-uracil), can be administered
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intra-arterially with only moderate leukopenia or throm-
bocytopenia if the animal is submitted to haemodialysis,
peritoneal dialysis or intravenous infusion of mannitol.'
The removal of protein-bound drugs can be further en-
hanced if parabiotic cross-dialysis with an animal of the
same or of a different species is employed instead of the
usual dialysing fluid.' These exr;eriments have never-
theless not been confirmed in man.
A uniformly accepted schedule of treatment is still
lacking even with regard to those tumours that are very
sensitive to chemotherapy. A wide range of variables in
the proposed treatments is indeed encountered, such as
the choice of the drug, its dosage, the duration of the
treatments with or without further cycles of maintenance,
consolidation or reinduction, the use of a single agent or
of combinations of several drugs, the adoption of contin-
uous or of intermittent patterns of administration. etc.
The drug combinations can be employed either by the
simultaneous administration of several compounds or by
the _consecutive use of single drugs. A recent method of
sequential treatment is that of synchronisation, using
drug that act on different phases of the reproductive
cycle.
It can be achieved by the administration of antimitotic
agents as the initial part of the treatment. followed by
drugs that act during the subsequent S phase.
Together with chemotherapy, radiation or other com-
plementary measures can be employed with the aim of
increasing the efficacy of anticancer treatment.
A synergic action can be obtained by hyperoxygenation,
hyperthermia, immunotherapy, or the administration of
substances such as insulin, which may increase penetration
of drugs into the cells, or which may stimulate histiocytic
activity or phagocytosis, such as oestrogens. To this lack
of a uniformly standardised form of treatment, the con-
tinuous introduction of new drugs into the therapeutic
armamentarium should be added.
Chemotherapy is therefore still in an experimental,
growing phase. Any valid and lasting progress can only
be achieved by controlled clinical trials. A large number
of cases is necessary, with prolonged follow-ups, based
on thorough knowledge of cell kinetics. This requires
carefully planned and rather complex prospective studies
that have only been employed in the field of bladder
tumours to a small degree. Most reports deal with only
a few cases, and can generally be found only within the
text or tables of statistical surveys on chemotherapy in
general.
It is likely that the knowledge of relatively poor res-
ponsiveness of bladder tumours to chemotherapy has
discouraged most urologists: and also likely, on the other
hand, that a wider clinical experience, based on controlled
trials, might lead to a significant improvement of future
results. There is no doubt that chemotherapy of bladder
tumours is difficult and only seldom rewarding, but it
would be wrong to ignore the value of certain achieve-
ments, some of which are of the greatest interest. We
emphasise, in particular, the following aspects of this.
topic: topical therapy of papillary growths; systemic
chemotherapy of inoperable carcinoma, either alone or
in association with radiotherapy; and chemoprophylaxis.
INTRAVESICAL TREATMENT
The rationale for a topical treatment of papillary neo-
plasms with chemotherapeutic agents has already been
discussed in many reports. Its practical value has been
established by the results reported in most series.
The literature is particularly exhaustive with respect
to Thio-tepa. a multi functional alkylating agent. This
substance has generally been employed with success, and
partial or (ven total regressions of papillary bladder
tumours have been observed.
Other drugs have also been employed for this purpose,
with rather good results, such as other alkylating drugs
(Epodyl-a peptidic complex of phenylalanine mustard
named Peptichemio, mechlorethamine), some antimitotic
agents (colchicine. podophyllin and their derivatives such
as SP-I), or antibiotics (adriamycin, daunomycin, bleo-
mycin and Mitomycin-C). Antimetabolites, such as 5-
fluoro-uracil (5-FU). and methotrexate display very little
effectiveness if employed by intravesical instillation.
Our results, which are not unsatisfactory, were reported
in a recent article." It has been confirmed that chemo-
therapy can lead, in some cases, to the complete dis-
appearance of papillary bladder growths, whether single
or multiple or diffuse. When regression is obtained it is
particularly valuable in the case of diffuse papillomatosis,
where it can prevent a mutilating and serious procedure
such as cystectomy.
Partial rf gressions can also be very useful since they
may allow the performance of conservative transurethral
or surgical interventions that were impossible before.
In other instances they lead to subjective improvement or
to a reduction in blood loss. It Should be recognised that
such therapeut:c endeavours are still empirical and in-
completely understood. The doses have been arbitrarily
selected so that the amount administered by intravesical
instillation is usually equal to a daily parenteral dose or
somewhat less. Tt is not certain that this represents the
optimum dose and that lower amounts cannot be equally
effective.
The usual technique is that of administering, at weekiy
intervals. and for a variable number of times, intravesical
instillations of a given drug, diluted in an average volume
of 30 ml, to be kept in the bladder for I - 2 hours.
A change in position is also suggested, from the prone
to the supine. and to the lateral positions on both sides.
This step has proved unnecessary in our experience and
can be safely omitted. We prefer instead to avoid any
restriction of activity, so that the treatments can be given
on an outpatient basis.
It should be noted that intravesical treatment is not
without risk. Some cases of severe. or even lethal mvelo-
toxicity have been described after topical administr~tion
of Thio-tepa. In addition it should be stressed that
therapeutic activity is not constant. being totally absent
in about one-half of treated patient" especially in those
with tumours of comparatively large size or in an advanced
stage.
These considerations have led us to investigate the
following points:
(a) Use of less toxic drugs, different from Thio-tepa.
(bl Different ways of administration.
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(c) Preliminary study of the responsiveness of a gi~en
tumour to various agents. .
(d) Fare and distribution of various drugs after intra-
vesical administration under normal and patholo-
gical conditions, with special reference to reabsorp-
tion into systemic circulation and fixation to the
tumour and to normal tissues, including the deeper
layers of bladder wall.
Our investigations are still in progress, but some pre-
liminary impressions can be anticipated.
Use of Less Toxic Drugs
Drugs other than Thio-tepa can be used intravesically
with some good results. The other alkylating agents
employed, namely cyclophosphamide, Trenimon, Pepti-
chemio and mecWorethamine, often produce severe symp-
toms of chemical cystitis. Adriamycin and daunomycin
are instead well tolerated by the bladder but it should be
noted that intravesical treatment with drugs other than
Thio-tepa has never given rise to complete regression of
bladder tumours, except in one case treated with
mecWorethamine.
DiJferent Ways of Administration
Prolonged bladder perfusions with some drugs (deme-
colcine, adriamycin, Peptichemio, 5-FU), either alone or
in sequential association by means of a three-way catheter,
were well tolerated locally and systemically. This holds
true even when for several consecutive days daily doses
were used that were as high as those employed for a
single instillation, and even when the treatment was
started soon after a transurethral procedure. No toxic
effects were ever observed, due to Iow concentration of
drugs (the daily dose being dissolved in I - 2 litres), so
that inflammatory reaction is practically absent and re-
absorption minimal, despite prolonged contact. The number
of treated cases is still small, but sufficient to show that
objective and even complete regressions of papillary
tumours can be obtained by continuous vesical perfusion.
Furthermore, this method allows synchronisation therapy
without any increase of its toxic side-effects. It can also
be associated with hyperthermia and local hyperoxyge-
nation. In addition, it is possible to utilise the antimeta-
bolites that are ineffective if employed for short contact
periods.
Tumour Responsiveness to VariollS Agents
The observation that neoplasms, apparently identical
from either a cystoscopic or a histopathological standpoint,
can display a completely different response to a topical
treatment, has stimulated us to study the possibility of
obtaining preliminary information on the sensitivity of
a given tumour to various drugs, so that the most effective
one might be selected.
Heterotransplantation into the hamster cheek-pouch,
followed by the measurement of growth curves of grafted
11
tumours in groups of animals treated with various drugs
is certainly a fascinating technique, but cannot be employed
in clinical practice due to its length, complexity and
cost.'
In vitro cultures of neoplastic cells in liquid media, asso-
ciated with the measurement of inhibition of the uptake
of tagged precursors (tritiated thymidine and leucine), are
of value in detecting which substances are most effective
in blocking DNA and protein synthesis. Expensive equip-
ment is required and the technique is ratb,er complex and
therefore not amenable to wide clinical use.'
Another method is available, which is simpler, more
rapid and can be adopted in every average laboratory.
It is based on the property of active drugs to inhibit the
dehydrogenase activity of tumour cells, as shown by
lack of decoloration of methylene blue around the discs
containing the effective drugs." Unfortunately, this simple
method is not constantly reproducible. Other simple
methods can be employed, which detect cytotoxic effects.
According to Lunglmayr's technique: a comparative
cytological examination is performed, before and after
an intravesical treatment. Our experience with this method
has been rather unrewarding, despite some modifications.
Neither differential counts with respect to the extent of
cytoplasmic or nuclear changes, nor fluorescence micro-
scopy or vital staining seem to improve the reliability of
this method, as we have observed by examining a large
number of smears of either exfoliative or contact cytology
as well as histological sections.
According to our experience, we consider that -a wide
range of error cannot be avoided by using methods based
on cytotoxicity, so that the criteria for evaluation are
gross and of limited reliability.
We found it especially interesting to study the actual
penetration of chemotherapeutic agents into the nuclei
of tumour cells. This can be easily achieved with fluore-
scent drugs, such as adriamycin, daunomycin or other
substances such as Peptichemio, which can be chemically
bound to fluorescent compounds (tetracycline, fluorescein).
Autohistoradiographic methods can also be employed
in order to demonstrate the entrance of tagged anticancer
drugs into neoplastic cells following intravesical treatment.
It should be noted; on the other hand, that evidence is
lacking that the morphological demonstration of the
presence of drugs in the nuclei is proof of its anticancer
activity, in that particular setting.
The conclusion, at th.e present stage of our experience,
is that the reliability of any of the single methods is
limited, but that they may acquire a greater significance
. if their results are concurrent. We must admit, however,
that no universal antimitogram is available, that can be
applied as a routine in any laboratory for the study of
bladder tumours.
Drog Reabsorption and Fixation
The difference between the amount of a given drug
introduced into the bladder cavity and the amount
that is r.ecovered after one or two hours (by voiding and
subsequent repeated vesical rinsing), can be easily esta-
blished. The amount of the drug that has disappeared
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is not only related to reabsorption through the bladder
wall and to escape into the systemic circulation, but also
to fixation onto the tissues. This can be demonstrated
again by the use of fluorescent or tagged drugs after
variable periods of contact. Using adriamycin we were
able to observe that substantial traces of the drug were
detectable not only in the tumour but also in the deep
layers of the bladder wall.
The amount of Thio-tepa and other alkylating agents
that disappears after intravesical instillation is instead
measurable by colorimetric methods. It is rather small
in the healthy bladder, but it can reach 80% or even
more in cases of multiple and large tumours, as well as
after transurethral or open surgical procedures. The same
behaviour can be demonstrated for adriamycin, although
the extent of reabsorption seems to be comparatively
lower.
SYSTEMIC CHEMOTHERAPY
Systemic chemotherapy of infiltrating carcinoma of the
bladder is followed by only limited success, according
to the experience of several authors. The use of alky-
lating agents has produced no consistent results, in spite
of the report by Fox," that some objective regression
and symptomatic relief can be obtained if very high
doses of cyclophosphamide are employed.
Relativ.ely better results can be obtained by the use of
antimetabolites. Methotrexate has been employed by in-
fusion into the internal iliac artery with some good results,
although the value of this method in pelvic tumours is
limited by the extensive escape of the drug into the
systemic circulation, and still remains to be assessed.
It cannot be d.enied, however, that striking results were
obtained by Carbone et al.' by intra-arterial infusion of
a cocktail of drugs into the hypogastric artery after
ligation of all collateral branches, except the vesical ones.
A wider experience of the use of 5-FU as the
only treatment, has failed to confirm the encouraging
results described in the early reports. Statistical studies
would even suggest that it is not superior to a placebo, at
least following the protocol developed by Prout et al."
Contrariwise, the association of 5-FU to cobalt therapy
has proved successful in our hands as well as in other
series, not only as a pre-operative measure, but also in
the treatment of inoperable caSeS.n ,12
As far as antibiotics are concerned, no conclusions can
be drawn regarding daunomycin, as the experience is too
limited.
Adriamycin appears, however, to be one of the most
promising drugs, as shown by the high number of regres-
sion--even greater than 50%-reported by Frey et al.]·
This is at variance with the limited success in Whitmore's"
experience.
Objective regressions of the original tumour or of its
metastases, apart from relief of pain and other distressing
symptoms, can be obtained in some of the patients
treated with Mitomycin-c. This antibiotic was found,
on the other hand, to be the most effective drug in
experiments performed on a vesical cancer transplanted
in the hamster. Its toxicity in clinical u'se can be greatly
reduced by slow intravenous drip infusion.
The preliminary favourable experience reported by
Japanese work on carcinophyllin has not yet been con-
finned.
Bleomycin is another drug that deserves careful con-
sideration, in spite of the fact that reports on its use are
still contradictory. Very recent information about the
experience of the co-operative group on urological on-
cology of the European Organization for Research on
the Treatment of Canc.er (OERTC), shows the following
data out of 30 bladder cancers treated with bleomycin:
1 interruption of therapy; 1 death; 2 total regressions;
3 partial regressions greater than 50 %; 7 partial regressions
of more limited magnitude; 2 subjective improvements;
and 13 failures. The percentage of objective regressions
was therefore equal to 40%.
Among mitostatics, vinca alkaloids are almost totally
ineffective, whereas preliminary data from the OERTC
urological co-operative group seem to indicate that VM-26,
a new podophyllin derivative, is another promising drug,
worthy of being extensively evaluated in the treatment of
bladder cancer.
Hydroxyurea was also considered a promising drug.
The excellent results reported in over three-quarters of
their patients by workers from USA and Italy are not in
keeping with the experience of other authors. At any
rate, even according to the most optimistic reports,
regressions have always been transient and no patient
has been cured. Little is known about the value of tbe
various drug combinations and little can be found in the
literature.
Our personal experience reported in 1970' refers to
102 systemic treatments using various fonns of chemo-
therapy. Follow-ups were obtained in only 90 cases, and
statistical analysis was performed as a part of a more
extensive study with the help of a computer. It was
concluded that the percentage of remissions was relatively
good, being as high as 41 % of cases, although it should
be stressed that in 30% such remissions were only partial
and short-lived, whereas regressions greater than 50%
of the original tumour size and lasting for at least one
month were less than 10%.
No drug has given consistent results or shown a clear-
cut superiority over other available agents. Mitomycin-C,
which was among the drugs that we had more extensively
employed, yielded, however, some good results within
the limited range of success that can be anticipated.
In the whole group, objective regressions were excep-
tional in stage T4, rare in T3, relatively more frequent
in stage TI. Our best results were obtained in the patients
treated with 5-FU, together with cobalt teletherapy. The
number of patients is comparatively high, with follow-ups
longer than 3 years in two-thirds of cases. A retrospective
analysis showed that the mortality rate was higher and
remissions less frequent in a comparable group of patients
treated by radiation alone. The higher mortality in this
latter group is very likely to be related to the fact that
the average dose of radiation was significantly higher,
especially because many patients had been submitted to
repeated cycles of cobalt therapy.
The patients in both groups, except 2, were in a
very advanced stage, either T3, or mostly T4. Our results
support the contention of a renal synergism between
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5-FU and radiation therapy, and are in accordance with 
the suggestion that, in such cases, focal radiation dose 
can be successfully limited in a range between 4 000 and 
6000 rads. The combined treatment, 5-FU plus radiation, 
was followed in 7% of cases by an apparent cure, which 
persisted after a follow-up of at least 3 years. In another 
6% the treatment brought about a partial regression 
which was of such extent as to allow a radical surgical or 
transurethral procedure in patients who were considered 
locally inoperable before the treatment. A partial regression 
of the tumour was obtained in 47% of patients. 
The duration of the remissions was prolonged for at 
least 3 months in about half of the responsive cases. 
It was clearly shown that the results were much better 
if the patient had not been submitted to previous irradia- 
tion or  surgery, where complete failures were uniformly 
observed. 
Our further experience is substantially in agreement 
with our earlier results. New drugs have been recently 
checked and clinical trials with others, such as VM-26, 
are still in progress. 
Peptichemio (peptidic complex of phenylalanine mus- 
tard), has yielded some successful results, both palliative 
and objective, among which was the regression of pul- 
monary metastases of a bladder cancer. 
Our experience with adriamycin is not as good as that 
of our colleagues from Texas." We have nevertheless 
observed some good results. The almost complete re- 
gression of an anaplastic carcinoma in a young patient 
permitted the radical removal of a bladder that was 
initially fixed to the pelvic wall. , 
No demonstrable results were obtained in any of our 
3 patients treated with bleomycin. 
Controlled clinical trials are presently in progress, 
including sequential polychemotherapy with VM-26, adria- 
mycin, 5-FU, Mitomycin-C, and Peptichemio. This seems 
to be a very useful treatment, but it is too early for a 
definite opinion. It can be concluded that, in a difficult 
field such as the treatment of advanced bladder cancer. 
the best results can be obtained by the use of all available 
therapeutic measures. 
Surgery and radiation still remain, of course, of primary 
importance. Chemotherapy, on the other hand, can be 
combined with both and improve the results of irradiation. 
It may offer valuable results when other methods of 
therapy cannot be successfully employed, and remains 
the only treatment available in patients with distant 
metastases. It should be remembered that in such cases, 
as well as with inoperable patients, chemotherapy can 
offer, if not a permanent cure, at least some valuable 
palliation and temporary regression. 
In view of the fact that in the latter category the 
aim of chemotherapy is merely to achieve palliation, 
(permanent cures being impossible at the present time). 
it is not advisable to push chemotherapy to the highest 
possible doses which jeopardise life in poor-risk patients, 
and produce severe and distressing toxic symptoms. This is 
contrary to tk goal aimed at. Subjective remission can 
usually be obtained with relatively low doses that do not 
lead to the level of toxicity that should ~ecessarily be 
reached in other fields of oncology. where a curative 
action can be anticipated. 
CHEMOPROPHYLAXIS 
The most useful indication for the use of chemothera- 
peutic agents in urology can probably be found in 
prophylaxis after adequate treatment of non-infiltrati~g 
papillary bladder tumours. This has been clearly shown 
in several reports dealing with Thio-tepa, mechloretha- 
mine, podophyllin derivatives (all used intravesically), and 
confirmed in our own experience during the past 8 
years." 
Successful treatment of papillary bladder tumours by 
transurethral or open surgery was followed in our control 
group by a rather high recurrence rate (60% within two 
years). We have used various prophylactic measures: 
addition of Trenimon or  other anticancer drugs to the 
irrigating fluid during and after transurethral resection; 
intravesical instillation of Thio-tepa, 5-FU, daunomycin, 
adriamycin, Peptichemio or SP-1; administration of various 
drugs intravenously (5-FU, Mitomycin-C) or orally 
(cyclophosphamide, hydroxyurea, methotrexate, procar- 
bazine, podophyllin glucosides, ascorbic acid and others). 
The oral drugs that were more frequently employed 
were administered once a week in a single dose (hydro- 
xyurea: 2 g, procarbazine, paraphyllin 200 mg, or metho- 
trexate 10 mg). Many patients were lost to follow-up. 
and up to May 1971 only 134 could be evaluated, 94 
of whom were given prophylactic treatment and 40 
controls were given no treatment. 
Intravesical prophylactic treatment has given the best 
results. Recurrences were observed only 3 times out of 
14 patients treated with Thio-tepa, administered initially 
at weekly, then at monthly intervals. Only 1 recurrence 
was discovered out of 7 patients treated with daunomycin, 
and 2 recurrences occurred in 8 patients given adria- 
mycin, both by intravesical instillation. 
The prophylactic use of antiblastic drugs added to 
irrigation fluids is not without some efficacy, though the 
action is less evident. When intravesical prophylactic 
instillations are interrupted, recurrences often appear, 
so that it is advisable to continue treatment for one or 
even two years. Oral drugs were shown to produce 
valuable preventive effects and their use is particularly 
advocated in cases where intravesical instillations are 
impractical or impossible. They can also be employed for 
maintenance treatment after the first months of intravesi- 
cal medication. 
Oral treatment is limited by the low urinary excretion 
of most substances. The alkylating agents, in particular. 
are very poorly excreted by the kidneys. In keeping with 
the theory, a number of drugs that reach relatively high 
urinary concentration display a good prophylactic action. 
This is shown by the low number of recurrences in 
patients treated with hydroxyurea (80 - 90°L of the ad- 
ministered dose excreted in the urine in 24 hours)--3 
recurrences out of 13; procarbazine (70"" urinary excre- 
tion)--1 recurrence out of 11; methotrexate (75% 
excretionel recurrence out of 14. - 
Our experience with other drugs, administered either 
orally or intravenously, was inconclusive. No recurrences 
were observed in 4 patients with superficial muscle in- 
vasion, where topical Thio-tepa was supplemented by 
intravenous Mitomycin-C and 5 - N .  Follow-up exceeded 
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5 years in one case. Some toXlClty cannot be avoided
with this combined treatment, but we believe that such
vigorous treatment may be justified in cases where
some doubt is present in the surgeon's mind about
complete removal of the tumour. In all the other cases
wh.ere only one drug was employed, no significant toxic
effect was ever observed, apart from mild gastric distur-
bances afier intake of Natulan. From our experience
during the past year (the analysis is not yet complete), it
can be anticipated that the established trends will be
confirmed, in spite of a somewhat higher percentage of
recurrences occurring in the patients given oral hydro-
xyurea.
It is likely that this reflects a different selection of
cases, since we have encountered a higher number of
patients with marked urothelial instability, as shown by
a tendency towards multiple or diffuse papillomatosis
with a past history of frequent recurrence. Patients showing
this pattern of urothelial disease should probably be placed
in a different category from the more usual type of
papilloma, and be treated with a higher dose of oral
chemoprophylactic agents, e.g. 2 g of hydroxyurea two
to three times a week.
The theoretical background for oral prophylactic
treatment appears to be sound, not only because a drug
that reaches a higher urinary concentration shortly after
oral administration can display, without a need for
urethral catheterisation, an action that is similar to that
of a drug directly introduced into the bladder, but also
because it acts on the whole urothelial surface, and not
only on the bladder mucosa. It should be emphasised, in
addition, that the toxicity of hydroxyurea is minimal,
even for protracted treatments using high daily doses.
Our preliminary experience with chemoprophylaxis for
papillary bladder tumours is very encouraging, but greater
experience is needed. We have started a polycentric con-
trolled randoollsed trial and would be very grateful to
any colleague who would join this programme, so that
more valuable cumulative experience may be obtained.
REFERENCES
I. Pasqualino, A., Pavone-Macaluso, M., Madonia, S. and Galletti,
P. M. (1969): Minerva med., 60, 687.
2. Pavone-Macaluso, M., Alexander, R. W., Geering, R. B. and
Galletti, P. M. (1964): Trans. Amer. Soc. Artif. Intern. Org., 10,
285.
3. Pavone-Macaluso, M. (1971): Brit. J. Uro!., 43, 701.
4. Burt, F. B., Pavone-Macaluso, M., Horns, J. W. and Kaufman, J. J.
(1966): J. Uro!., 95, 51.
5. Fumari, S., Pavone-Macaluso, M., Veroux, G. and Mattea, E. (1970):
Proceedings of the 43rd Meeting of the lcalian Society of Urology,
Florence, 1970, pp. 405 - 413.
6. Di Paolo, J. A. and Dowd, J. E. (1961): J. Nat. Cancer Inst., 27,
807.
7. Lunglmayr, G., Kellner, G. and Zech, K. (1970): Uro!. Int. (Basel),
25. 493.
8. Fox, M. (1967): Brit. J. Uro!., 37, 399.
9. Carbone, G., Gasso, G .• Glglio, V., Montandon, C. and Inga, G.
(1970): Proceedings of the 43rd Meeting 0; the Italian Society 0;
Urology. '-'al. 2, DiscUSSlOns and CommunicQejons, Florence 1970.
pp 51 - 66.
10. Prout. G. R. jun., Bross, I. D. J .• Slack, N. H. and Ausman, R. K.
(1968): Cancer, 22, 926.
I I. Kaufman, J. J. and Stein, J. J. (1965): Cancer Chemother. Rep.,
48, 56.
12. LatlUco, C., Pavone-Macaluso, M. and Verace, V. (1967): Archivio
Siciliano di Medicina e Chirurgia. 8. 569.
13. Frci, E. Ill. Luce, J. K. and Middleman, E. (1972): Proceedings 0;
an International Symposium on Adriamycin. Milan 1971. Berlin:
Springer Verlag.
14. Whitmore. W. F. Personal communication.
15. Pavone-Macaluso, M., .Caramia, G. and Rizzo. F. P. (1971): Uro!.
int. (BaseI). 26, 379.
